Related Experiment Video

Updated: Sep 3, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities

Garrett W Cooper1,2, Andrew L Hong1,2,3

  • 1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.

Cancers
|July 27, 2022
PubMed

Insights

Loss of the SMARCB1 gene, crucial for chromatin remodeling, drives rare aggressive cancers like MRT, ATRT, and RMC. Understanding these mechanisms aids in developing targeted therapies for these deadly tumors.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • SMARCB1 is a key component of the BAF complex, essential for chromatin remodeling.
  • Loss of SMARCB1 is linked to rare, aggressive cancers including malignant rhabdoid tumor (MRT), atypical teratoid rhabdoid tumor (ATRT), and renal medullary carcinoma (RMC).

Purpose of the Study:

  • To review the mechanisms by which SMARCB1 loss contributes to tumor formation.
  • To explore how these mechanisms inform the development of targeted therapies for SMARCB1-deficient cancers.

Main Methods:

  • This review synthesizes existing research on SMARCB1's role in cancer.
  • It examines the epigenetic and transcriptional dysregulation resulting from SMARCB1 loss.
  • The review discusses therapeutic strategies targeting identified mechanisms.

Main Results:

  • SMARCB1-deficient tumors exhibit stable genomes, providing insights into epigenetic regulation in cancer.
  • Tumorigenesis is associated with aberrant enhancer/promoter regulation and dysfunctional transcription.
  • These findings highlight potential therapeutic vulnerabilities.

Conclusions:

  • Loss of SMARCB1 initiates specific aggressive cancers through epigenetic and transcriptional alterations.
  • Understanding these pathways is critical for designing effective targeted therapies against SMARCB1-deficient tumors.
Keywords:
SMARCB1-deficient cancerchromatinepigeneticsrhabdoid tumorstructuretherapeutics

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K
CD Spectroscopy to Study DNA-Protein Interactions06:48

CD Spectroscopy to Study DNA-Protein Interactions

Published on: February 10, 2022

6.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K